January 27, 2015 2:40 PM ET

Life Sciences Tools and Services

Company Overview of Rubicon Genomics, Inc.

Company Overview

Rubicon Genomics, Inc. engages in the development and commercialization of sample-specific nucleic acid library preparation products for use in research and clinical testing on next-generation sequencing (NGS), microarray, and q-PCR platforms. The company creates molecular biology tools for genetic, epigenetic, and expression analysis of various samples to facilitate gene-based research, drug development, and diagnostics. Its products include ThruPLEX DNA-seq kits to generate DNA libraries with expanded multiplexing capability and diversity with lower duplication rates; PicoPLEX DNA-seq kits to streamline library preparation and PicoPLEX process used by IVF clinics for pre-implantation genet...

4743 Venture Drive

Ann Arbor, MI 48108

United States

Founded in 2000

Phone:

734-677-4845

Fax:

734-477-9902

Key Executives for Rubicon Genomics, Inc.

Chairman
Age: 65
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer
Vice President of Business Development
Compensation as of Fiscal Year 2014.

Rubicon Genomics, Inc. Key Developments

Rubicon Genomics Adds New Global Distributors; Hires Karl Hecker as Vice President of Product Development

Rubicon Genomics, Inc. announced that it has signed agreements with new distributors in Europe, North Africa and Asia to further expand the availability of its DNA library preparation products for arrays and Illumina(R) next-generation sequencing (NGS) platforms, including ThruPLEX(R) DNA-seq, PicoPLEX(TM) DNA-seq, and PicoPLEX WGA Kits. Rubicon's new distributors include CliniSciences in France, Spain and North Africa; Nerliens Meszansky AS in Norway; Shanghai Nanodigmnio Biotechnology Co., Ltd, in China; and GeneLabs Life Science in Taiwan. Rubicon announced that Karl Hecker, PhD, has joined the company as Vice President of Product Development. Dr. Hecker brings the Rubicon management team more than 15 years of life sciences and diagnostics product development expertise and over 25 years' experience in chemistry and molecular biology. At Invitrogen, he commercialized approximately 60 nucleic acid purification and isolation products in a three-year period.

Rubicon Genomics, Inc. Expands Distribution in Europe and Asia

Rubicon Genomics, Inc. announced that it has partnered with additional distributors globally to expand availability of its products, including ThruPLEX -FD Prep Kits and PicoPLEX-WGA Kits. Three new distribution partnerships have been signed for Europe. They include Amplitech for France, HPST for the Czech Republic and LuBio Science for Switzerland. Rubicon also completed new distribution agreements in Asia and the Middle East. They include Recenttec for Japan, Prisma Biotech for Taiwan and S.M. Chemical for Thailand. Custom Science will provide distribution services to Australia and New Zealand. A well-established local biomedical distributor is supporting sales of Rubicon's products in Qatar. ThruPLEX-FD Prep Kits for Illumina NGS platforms streamline library preparation for fragmented DNA/cDNA and reduce sample input amounts to picogram levels. ThruPlex-FD's patented technology delivers a highly efficient and user-friendly process that takes place in a single tube in less than 2 hours. ThruPLEX-FD provides consistent and reliable results for applications including DNA-seq, RNA-seq and ChiP-seq and is especially useful for clinical samples such as plasma and FFPE.

Utility of Rubicon Genomics, Inc.s' ThruPLEX(TM)-FD Kit Validates in Study Showing Liquid Biopsy

Rubicon Genomics, Inc. reported that its ThruPLEX(TM) -FD Prep Kits contributed to the success of a breakthrough study recently published in Nature that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment. The proof-of-principle study showed that by sequencing tumor exomes extracted from patient plasma samples, it is possible to track how metastatic cancer evolves to acquire resistance to cancer therapy. In patients with advanced breast, lung and ovarian cancers, the researchers derived tumor sequences using plasma samples taken during multiple courses of treatment. They were able to identify mutations associated with the emergence of resistance to cancer drugs including cisplatin, tamoxifen and gefitinib. The authors concluded that this non-invasive 'liquid biopsy,' based on tumor DNA that is released into the circulation, offers important advantages and could complement current invasive biopsy methods that can be uncomfortable and costly. ThruPLEX-FD Prep Kits are designed to provide sensitive and consistent sequencing from challenging samples containing small amounts of degraded DNA with minimum hands-on time. They leverage Rubicon's patented DNA repair and ligation methods to deliver more rapid and sensitive sequencing of plasma, formalin-fixed, ChIP and other fragmented DNA samples with increased throughput. This study illustrates how ThruPLEX-FD can be a valuable tool for generating the high quality genomic information that is essential for personalized medicine. For this study, the scientists used ThruPlex-FD to prepare libraries from very small quantities of circulating DNA extracted from plasma (as small as 2.3 ng of DNA.) After enriching for the exome fraction, pair-end sequencing of the samples were performed on an Illumina HiSeq 2500. ThruPLEX-FD is a streamlined single tube, three-step process that eliminates intermediate purifications, transfers, columns or gels. This decreases the likelihood of experimental variability, bias and contamination. DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time. A technician can prepare 192 ThruPLEX samples per day--a 15-fold increase in productivity compared to other methods. ThruPLEX-FD is designed and validated for use with samples as small as 50 picograms of human DNA and can be used with plasma, FFPE, or fragmented gDNA in FFPE for DNA-seq, RNA-seq and ChIP-seq applications. ThruPLEX-FD is currently available as 12 or 48-reaction, 12-index kits for sequencing on Illumina(R) HiSeq(R), MiSeq(R) and Genome Analyzer instruments. ThruPLEX-FD kits are being developed for additional formats and platforms.

Similar Private Companies By Industry

Company Name Region
EDC Biosystems, Inc. United States
Coating Place, Inc. United States
Pacific BioLabs Inc. United States
SafeBridge Consultants, Inc. United States
Velesco Pharmaceutical Services, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Rubicon Genomics, Inc., please visit www.rubicongenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.